ALNA — Allena Pharmaceuticals Share Price
Last trade - 00:00- $34.43m
- $3.90m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.32 | ||
| Price to Tang. Book | 1.32 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -131.26% | ||
| Return on Equity | -219.67% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Allena Pharmaceuticals, Inc. is a late-stage, clinical biopharmaceutical company. The Company is engaged in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The Company is focused on metabolic disorders that result in excess accumulation of certain metabolites that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease (CKD) and end-stage renal disease (ESRD). Its lead product candidate, reloxaliase, is an oral enzyme therapeutic developing for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate (UOx) levels and commonly associated with kidney stones, CKD and ESRD. Its second product candidate, ALLN-346, is an orally administered, novel, urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced CKD.
Directors
- Alexey Margolin CHM (67)
- Louis Brenner PRE (51)
- Richard Katz CFO (57)
- Geoffrey Swire COO (48)
- David Clark OTH
- Robert Alexander IND (51)
- Allene Diaz IND (57)
- Mark Fitzpatrick IND (58)
- Ann Miller IND (63)
- Gino Santini IND (65)
- Last Annual
- December 31st, 2020
- Last Interim
- September 30th, 2021
- Incorporated
- June 24th, 2011
- Public Since
- November 2nd, 2017
- No. of Shareholders
- 17
- No. of Employees
- 35
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 80,140,728
- Address
- 1 Newton Executive Park Ste 202, NEWTON, 02462-1435
- Web
- http://www.allenapharma.com/
- Phone
- +1 6174674577
- Auditors
- Ernst & Young LLP
Latest News for ALNA
Upcoming Events for ALNA
Q4 2021 Allena Pharmaceuticals Inc Earnings Release
Q1 2022 Allena Pharmaceuticals Inc Earnings Release
Allena Pharmaceuticals Inc Annual Shareholders Meeting
Similar to ALNA
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
ACADIA Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 12:57 UTC, shares in Allena Pharmaceuticals are trading at $0.43. This share price information is delayed by 15 minutes.
Shares in Allena Pharmaceuticals last closed at $0.43 and the price had moved by -70.97% over the past 365 days. In terms of relative price strength the Allena Pharmaceuticals share price has underperformed the S&P500 Index by -76.35% over the past year.
The overall consensus recommendation for Allena Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Allena Pharmaceuticals does not currently pay a dividend.
Allena Pharmaceuticals does not currently pay a dividend.
Allena Pharmaceuticals does not currently pay a dividend.
To buy shares in Allena Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.43, shares in Allena Pharmaceuticals had a market capitalisation of $34.43m.
Here are the trading details for Allena Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ALNA
Based on an overall assessment of its quality, value and momentum Allena Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Allena Pharmaceuticals is $5.06. That is 1077.84% above the last closing price of $0.43.
Analysts covering Allena Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$0.78 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Allena Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -50.06%.
As of the last closing price of $0.43, shares in Allena Pharmaceuticals were trading -55.21% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Allena Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.43.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Allena Pharmaceuticals' management team is headed by:
- Alexey Margolin - CHM
- Louis Brenner - PRE
- Richard Katz - CFO
- Geoffrey Swire - COO
- David Clark - OTH
- Robert Alexander - IND
- Allene Diaz - IND
- Mark Fitzpatrick - IND
- Ann Miller - IND
- Gino Santini - IND